More about
Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn
News
June 12, 2022
3 min watch
Save
Intramuscular recombinant Erwinia asparaginase active, safe in leukemia, lymphoma subsets
A phase 2/phase 3 study assessed intramuscular asparaginase Erwinia chrysanthemi (recombinant)-rywn for patients with acute lymphoblastic leukemia or lymphoblastic lymphoma who developed hypersensitivity to E. coli-derived L-asparaginase.
News
July 01, 2021
2 min read
Save
FDA approves Rylaze for acute lymphoblastic leukemia, lymphoblastic lymphoma
The FDA approved asparaginase erwinia chrysanthemi (recombinant)-rywn as a component of a chemotherapy regimen to treat certain adults or children with acute lymphoblastic leukemia or lymphoblastic lymphoma.